Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New hope for vaccine to fight rheumatoid arthritis, other autoimmune diseases

29.10.2002


Promising animal test results that could lead to a vaccine to fight rheumatoid arthritis, multiple sclerosis (MS) and other autoimmune diseases were announced by researchers at the Technion-Israel Institute of Technology. The vaccine reversed an arthritic-like disease in rats by mobilizing part of the immune system to protect joints under attack by other immune cells. The work was reported in two related papers in the September Journal of Immunology .



Autoimmune diseases, in which the immune system attacks the body’s own tissues, are among the most widespread of serious chronic diseases. In arthritis, immune cells attack the joints, while in MS, they attack the myelin sheaths of nerve cells.

Current treatments involve either steroids, which fight inflammation caused by the immune system attacks, or immuno-suppressant drugs, which depress immune system function generally. Both these approaches create serious side effects and can only slow, but not stop, the progress of the diseases. They are also effective mostly at very early stages of each disease.


The new approach, in contrast, tries to rally one part of the immune system to fight the part that is attacking the body’s tissues. "We know that, in autoimmune diseases, immune cells use chemical markers, called cytokines and chemokines, to induce inflammation that destroys organs," explains Dr. Nathan Karin of the Technion’s Department of Immunology and the research team leader. "These proteins also attract white blood cells that, in the case of arthritis, attack joint tissues, and in the case of MS, attack brain components. Our method helps the immune system itself interfere with this process."

In untreated arthritis, part of the immune system detects one of the chemical markers, called IP-10, recognizes that it is wrongly labeling the body’s own cells for attack, and destroys it. But while these naturally produced antibodies can slow, they cannot stop the progression of these diseases. In effect, there is a "civil war" within the immune system itself, with one part attacking and the other part protecting the body’s own cells. The new approach seeks to help the "good" part of the immune system in its fight with the "bad" or autoimmune part.

The researchers first identified that IP-10 is one of the specific proteins responsible for the progression of these diseases, and more importantly that the immune system tries to restrain the harmful activity of IP-10 by producing auto-antibodies against it. They then generated a special vaccine that amplifies the production of these beneficial antibodies. This vaccine rapidly suppressed experimentally induced rheumatoid arthritis and MS.

Dr. Karin hopes that for rheumatoid arthritis this approach will replace older treatments, which are extremely expensive and require many repeated immunizations, and that it will also open new horizons for the therapy of MS.

"We are hopeful that the gene-based vaccine will be much better, since only a few vaccinations are needed to train the immune system to destroy IP-10, and the rat results indicate that chronic relief may be possible," says Karin.

While the vaccine will interfere with IP-10 when the immune system uses it to label actual invaders such as bacteria, Karin does not expect this will cause serious side effects.

"There are some 50 chemicals that the immune system uses to label cells to be attacked," he points out. "Knocking out one will not seriously weaken the immune system’s response to infection or cancer. But in autoimmune diseases, where one part of the immune system is fighting another, eliminating IP-10 will shift the balance, giving the edge to the part that is protecting the body."

The next step is to move towards clinical tests of the vaccine in humans. Clinical tests are now planned for MS patients, and the group is negotiating with an as yet unnamed major U.S. pharmaceutical company.


The Technion-Israel Institute of Technology, known as "Israel’s MIT," is Israel’s leading scientific and technological center for applied research and education. It commands a worldwide reputation for its pioneering work in computer science, biotechnology, water-resource management, materials engineering, aerospace and medicine. Based in New York City, the American Technion Society (ATS) is the leading American organization supporting higher education in Israel.


Martha Molnar | EurekAlert!
Further information:
http://www.technion.ac.il/

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

Im Focus: Fraunhofer ISE Develops Highly Compact, High Frequency DC/DC Converter for Aviation

The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.

Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

UTSA study describes new minimally invasive device to treat cancer and other illnesses

02.12.2016 | Medical Engineering

Plasma-zapping process could yield trans fat-free soybean oil product

02.12.2016 | Agricultural and Forestry Science

What do Netflix, Google and planetary systems have in common?

02.12.2016 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>